Health & Bio

BeiGene wins accelerated FDA nod for Beqalzi in relapsed MCL

May 13 approval for BCL-2 inhibitor in recurrent/refractory mantle-cell lymphoma. AbbVie Venclexta now faces new competition in hematologic oncology.

Primary sources · 2
STAT NewsDrugs.com
← View the full 2026-05-18 (Mon) issue
What you're reading now arrives in your inbox daily at 21:00 UTC.

Get today's brief every day at 21:00 UTC

7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.

Past issues →